Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlookbusinessinsider·Aug 17 at 12:16 AMPSTV0.00%
Cerenome Reports Second Quarter 2026 Financial Results and Business UpdateUnusual Whales·Aug 14 at 03:17 PMPSTV0.00%CNSY+2.33%
Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 millionPUBT·Aug 14 at 03:16 PMCNSY+2.33%PSTV0.00%
Plus Therapeutics amends bylaws to reflect corporate name change to CerenomePUBT·Aug 4 at 04:34 PMPSTV0.00%CNSY+2.33%
Plus Therapeutics to trade on Nasdaq as Cerenome under CNSY ticker from Aug. 3PUBT·Jul 31 at 07:32 AMPSTV0.00%CNSY+2.33%
Cerenome Launches as an Integrated CNS Oncology Company | PSTV Stock NewsStockTitan·Jul 30 at 11:30 PMPSTV0.00%CNSY+2.33%
Plus Therapeutics signs Medical Mutual coverage deal for CNSide CSF tumor cell assay in Ohio, KentuckyPUBT·Jul 21 at 06:30 AMPSTV0.00%CNSY+2.33%
Plus Therapeutics partners with Genomic Testing Cooperative to add NGS to CNSide CSF assay platformPUBT·Jul 16 at 06:31 AMPSTV0.00%CNSY+2.33%
From Buybacks to Insider Buying: U.S. Mid-Caps Signal Capital ShiftGlobal Report·Jul 14 at 06:47 AMBDX+2.33%AB+0.67%
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases MonitoringUnusual Whales·Jul 14 at 06:31 AMPSTV0.00%
Plus Therapeutics flags availability of CNS cancers guidelines update releasePUBT·Jul 14 at 06:31 AMPSTV0.00%CNSY+2.33%
